Answers are grounded in this paper and cite their sources.
Systematic literature review highlights organoid applications in drug candidates for colorectal cancer, suggesting broader utility in complex diseases.
What is Known and Objective Drug repurposing offers a time‐ and cost‐effective means for drug development. Accordingly, the accurate prediction of human efficacy is crucial for its success. Organoids have emerged as valuable tools for evaluating compound efficacy in three‐dimensional environments closely resembling in vivo organs. However, a comprehensive overview of their application in drug repurposing is lacking. This systematic literature review discusses the origins, applications, and target diseases of organoids employed for drug repurposing. Methods A systematic search of original articles published up to March 5, 2025, was conducted in PubMed using the keywords “organoid” and “drug repurposing.” Trends in publications, organoid sources, research objectives, and target diseases were analyzed. Results and Discussion Research on drug repurposing using organoids initially emerged in 2016 and has grown rapidly since the 2020s. Patient‐derived tissue organoids, primarily derived from cancer tissues, are the most used. Organoids derived from pluripotent stem cells are mainly utilized for organs that are difficult to obtain from human tissues. These organoids are most frequently used for evaluation of the efficacy of repurposed drug candidates identified through other methods as well as for the primary screening of existing drug libraries, demonstrating broad utility for drug repurposing research. Most target diseases are cancers, with colorectal cancer being predominant. Organoids are anticipated to play increasingly important roles in drug repurposing, particularly for organs with limited tissue availability and complex three‐dimensional structures, as well as for a diverse range of diseases beyond cancer. What is New and Conclusions This study is the first to comprehensively review the use of organoids for drug repurposing. These findings provide valuable insights for researchers pursuing drug repurposing and encourage effective integration of organoids into drug repurposing strategies.
No takes yet. Share an insight, caveat, or question.
Ryo Okuyama (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: